[Federal Register Volume 66, Number 233 (Tuesday, December 4, 2001)]
[Notices]
[Pages 63064-63065]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-29938]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant Of Exclusive License: Prophylactic and/or 
Therapeutic Vaccines Against HIV and HCV

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a limited field of use exclusive worldwide license to practice the 
inventions embodied in U.S. Patent Application Serial Number 08/
375,100, filed January 19, 1995, entitled ``Peptomers with Enhanced 
Immunogenicity'' now United States Patent Number 5,750,332 issued May 
12, 1998 and U.S. Patent Application Serial Number 07/283,849 filed 
December 13, 1988, entitled ``Synthesis of Chloroacetyl and Bromoacetyl 
Modified Peptides for the Preparation of Synthetic Peptide Polymers, 
Conjugated Peptides and Cyclic Peptides' and now U.S. Patent Number 
5,066,716 issued on November 18, 1991 to AriaVax, Inc. of Bethesda, 
Maryland, U.S.A. The United States as represented by the Department of 
Health and Human Services is an assignee of these patent rights.

DATE: Only written comments and/or applications for a license which are 
received by NIH on or before February 4, 2002 will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to: Carol A. Salata, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7735 ext 232; Facsimile: (301) 402-0220; E-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: The patent application 08/375,100 describes 
the production of peptide multimers which maintain the conformation of 
the native proteins from which they are derived which are useful as 
therapeutic agents or immunogens and patent application 07/283,849 
describes a method used to incorporate bromoacetyl and chloroacetyl 
moieties on amino groups of synthetic peptides. This synthetic method 
can be used to prepare synthetic

[[Page 63065]]

peptide polymers, conjugated peptides and cyclic peptides.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license may be limited to the field of use 
as prophylactic and/or therapeutic vaccines against HIV and HCV. 
AriaVax, Inc. will use the technology of the inventions named above to 
develop formulations that will elicit antibodies that block infection. 
This prospective exclusive license may be granted unless within 60 days 
from the date of this published notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. 
Comments and objections submitted in response to this notice will not 
be made available for public inspection, and, to the extent permitted 
by law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 26, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-29938 Filed 12-3-01; 8:45 am]
BILLING CODE 4140-01-P